A shadow market for unapproved slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.
Investigational Drug Acquiring Traction Via Social Media
The experimental drug, which is still in research studies, is being advertised by online personalities for its alleged weight-reducing properties. Followers are urged to contact these profiles directly for supplier links, while also receiving promotional offers.
Thriving Commerce on Social Networks
Separately, a robust trade exists on messaging services, where communities with numerous of participants share comparison images, administration instructions and claims of rapid UK delivery. Sellers promote the drug there before redirecting buyers to other platforms for purchases.
Learning About Retatrutide
This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – GLP-1, GIP and glucagon. Preliminary studies suggest it could help individuals lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed online as the successor to Ozempic.
Medical Experts Express Worries
Nevertheless, doctors and chemists have warned that the sale of what is still an unapproved medication in the UK is a cause for concern and could result in individuals injecting substances of unknown origin.
Some professionals said the popularity for the experimental drug could be connected to the rising price of approved slimming treatments such as Mounjaro.
Legal Position and Implementation
Selling the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved medication that cannot be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.
Several content creators attempt to circumvent the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but promotion and supply can still breach pharmaceutical, advertising, and consumer laws, potentially leading to fines, prosecution or imprisonment.
Service Response and Material Removal
According to the social media company, the service has taken down problematic material and prohibited related hashtags and search suggestions. The organization said it was dedicated to keeping the service secure and allocating resources in strengthening compliance measures.
Online Trading Operations
Investigations also discovered communities with up to 9,000 participants marketing retatrutide using the platform's integrated search feature, which operates like a public directory. Typing “retatrutide” immediately brings up channels with numerous of users, populated with images of slimming results, positive reviews and step-by-step guides for mixing or injecting at residence.
Within moments of entering one group, a vendor shared WhatsApp details, where the majority of transactions take place. The vendor provided an guidebook and guaranteed delivery within 48 hours. When questioned whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a photo of a alleged testing documentation. None asked about weight, health issues or past usage.
Item Details and Pricing
Within these groups, messages display dark colored packages with Royal Mail stickers, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, prepared at home with purified liquid, or pre-filled pens typically priced at £160 for 20 milligrams. When asked how long a pen should last, sellers give conflicting responses ranging from a few weeks to “depends on your body”.
Service Moderation and Safety Measures
A spokesperson for Telegram stated it actively moderated harmful content on its service including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“Individuals are injecting materials they can’t verify. Even if the research behind retatrutide is sound, these online versions may not contain what they advertise,” stated Jason Murphy, the head of pharmacy at a pharmacy service.
A medical professional of Asda Online Doctor connected the increase in demand to recent price rises for approved weight-loss medications such as Mounjaro. “With costs increasing, patients are using social media. But fake injections are highly dangerous. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she explained.
Her staff has already seen individuals harmed by self-injection from unconfirmed sources. “We recognize the disappointment, but buying from messaging apps or WhatsApp is taking chances with your well-being,” stated the doctor. “These substances could be impure or incorrectly dosed.”
Producer Statement
A representative from the pharmaceutical company stated the substance was in phase 3 clinical trials and had not been reviewed or approved by any government authority globally. “Consequently at this point no one can sell [it] for personal consumption,” they explained, noting that any product “misleadingly claiming itself as a Lilly experimental product not yet approved … may expose patients to potentially significant health risks”.
